RxDoctor Payments Data

Anna Price

Family · Hammond, LANPI 1902553613

Payments from drug & device makers

$2,002in general payments, 2019–2025

Across 85 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • OPKO Pharmaceuticals, LLC$315
  • Bayer$305
  • Otsuka America Pharmaceutical, Inc.$202
  • Novo Nordisk$180
  • AstraZeneca$175
  • Teva Pharmaceuticals USA, Inc.$146
  • plus $679 from 13 others

What the payments were for

  • Food & beverage$2,002100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,002 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$87,051
Medicare patients
204
Services billed
1,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin35$32,081
RayaldeeCalcifediol21$24,212
EliquisApixaban15$15,107
KerendiaFinerenone12$12,714
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$958
Valsartan28$582
Hydralazine Hcl31$517
Potassium Chloride33$362
Pantoprazole Sodium27$358
Allopurinol45$314
Ezetimibe11$309
Metoprolol Succinate36$305
Levothyroxine Sodium23$304
Losartan Potassium38$269
Olmesartan Medoxomil24$268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
OPKO Pharmaceuticals, LLCRayaldee$315$24,21221 claims
PfizerEliquis$17$15,10715 claims
BayerKerendia$305$12,71412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.

Other family in Hammond

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →